Atousa Moghadam Fard

Atousa Moghadam Fard


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2025 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
FAFaezeh Almasi
Faezeh Almasi
FAFaeze Abbasloo
Faeze Abbasloo
NSNarges Soltani
Narges Soltani
MDMasoud Dehbozorgi
Masoud Dehbozorgi
AFAtousa Moghadam Fard
Atousa Moghadam Fard
PRParjin Rahmanpour
Parjin Rahmanpour

6 August 2024 in Brain Imaging and Behavior
Verified
Journal Article
Closed access
PDF file
MFMohammad Sadegh Fallahi
Mohammad Sadegh Fallahi
KSKianoosh Sahebekhtiari
Kianoosh Sahebekhtiari
HHHelia Hosseini
Helia Hosseini
MAMohammad Mahdi Aliasin
Mohammad Mahdi Aliasin
MNMasoud Noroozi
Masoud Noroozi
MMMahsa Mayeli
Mahsa Mayeli

22 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SKSaeed Khalili
Saeed Khalili
FZFatemeh Zeinali
Fatemeh Zeinali
AFAtousa Moghadam Fard
Atousa Moghadam Fard
STSeyed Reza Taha
Seyed Reza Taha
ANAndarz Fazlollahpour Naghibi
Andarz Fazlollahpour Naghibi
ZPZahra Payandeh
Zahra Payandeh
Macrophages are types of immune cells, with ambivalent functions in tumor growth, which depend on the specific environment in which they reside. Tumor-associated macrophages (TAMs) are a diverse population of immunosuppressive myeloid cells that play significant roles in several malignancies. TAM infiltration in malignancies has been linked to a poor prognosis and limited response to treatments, including those using checkpoint inhibitors. Understanding the precise mechanisms through which macrophages contribute to tumor growth is an active area of research as targeting these cells may offer potential therapeutic approaches for cancer treatment. Numerous investigations have focused on anti-TAM-based methods that try to eliminate, rewire, or target the functional mediators released by these cells. Considering the importance of these strategies in the reversion of tumor resistance to conventional therapies and immune modulatory vaccination could be an appealing approach for the immunosuppressive targeting of myeloid cells in the tumor microenvironment (TME). The combination of reprogramming and TAM depletion is a special feature of this approach compared to other clinical strategies. Thus, the present review aims to comprehensively overview the pleiotropic activities of TAMs and their involvement in various stages of cancer development as a potent drug target, with a focus on hematologic tumors.

21 August 2024 in medRxiv
Verified
Preprint
Open access
PDF file
AAAli Azargoonjahromi
Ali Azargoonjahromi
MAMitra Ashrafi
Mitra Ashrafi
DADonya Abroushan
Donya Abroushan
ERElham Ramezannezhad
Elham Ramezannezhad
MSMohammad Sadeghi
Mohammad Sadeghi
MMMahsa Mayeli
Mahsa Mayeli
High-density lipoprotein (HDL) cholesterol is typically protective for cognitive function due to its anti-inflammatory, antioxidant, and vascular health benefits. However, recent studies indicated that certain HDL subtypes might be associated with adverse brain structural changes, commonly seen in mild cognitive impairment (MCI). Thus, further research is needed to understand the intricate relationship between HDL levels and brain structure, potentially leading to more effective therapeutic strategies. The current study aimed to investigate the impact of HDL subtypes, such as XL_HDL_P, M_HDL_FC_PCT, M_HDL_P, M_HDL_C, and M_HDL_CE, as well as APOA1, on brain structure in individuals with MCI using tensor-based morphometry (TBM). The study analyzed ADNI data from subjects with at least two serial MRI scans, processed using the Mayo TBM-Symmetric Normalization (SyN) pipeline and SyN for longitudinal measures. The CDR and ADAS scores were used to assess the severity of cognitive impairment and disease progression in our study participants. Significant ROIs were identified from a Mayo Clinic training set, and TBM-SyN scores were computed. The significant correlation was considered with p-values less than 0.05. The study found significant negative effects of several lipoproteins on TBM scores in individuals with MCI. Specifically, XL_HDL_P, with an effect size of - 0.00145 (p=0.029), and M_HDL_FC_PCT, with an effect size of -0.00199 (p=0.0016), were linked to lower TBM scores. Similarly, M_HDL_P (−0.00138, p=0.028), M_HDL_C (−0.00140, p=0.025), M_HDL_CE (−0.00136, p=0.031), and APOA1 (−0.00149, p=0.017) also showed significant associations. These findings indicate that higher levels of HDL subtype cholesterol are significantly associated with reduced TBM scores, suggesting that elevated levels are linked to adverse structural brain changes, such as atrophy, in individuals with MCI, potentially contributing to cognitive decline.

2 June 2026 in Aging Clinical and Experimental Research
Verified
Journal Article
Open access
NNNafise Niknam
Nafise Niknam
NSNeda Songhori
Neda Songhori
NNNegar Nekahi
Negar Nekahi
MKMelika Kavian
Melika Kavian
FKFarbod Khosravi
Farbod Khosravi
PTParia Torabi
Paria Torabi
Focused ultrasound (FUS) has emerged as a non-invasive approach to transiently open the blood-brain barrier (BBB) and facilitate therapeutic delivery in Alzheimer's disease (AD). This systematic review evaluates current clinical evidence regarding the feasibility, safety, and reported biological and clinical outcomes of FUS-mediated BBB opening. A systematic search of PubMed, Scopus, and Web of Science was conducted in accordance with PRISMA 2020 guidelines and supplemented by Google Scholar. Human clinical studies employing FUS-induced BBB opening in AD were included. Risk of bias was assessed using the ROBINS-I tool for non-randomized studies. From an initial screening of 587 records, 27 studies met the inclusion criteria. Across these studies, FUS-mediated BBB opening was generally feasible and well tolerated, with no reports of irreversible procedure-related adverse events. Reported adverse effects were typically mild and transient, including localized headache, fatigue, or imaging-detected edema. Exploratory findings included heterogeneous changes in cognitive measures and regional amyloid-β biomarkers assessed by neuroimaging or cerebrospinal fluid analysis. Substantial variability in study design, target regions, sonication parameters, and outcome measures limited quantitative synthesis and definitive interpretation. Current clinical evidence supports the short-term feasibility and safety of FUS-mediated BBB opening in AD. However, the available data remain preliminary, and well-designed randomized controlled trials with larger cohorts, standardized imaging and cognitive endpoints, and longer follow-up are required to determine therapeutic efficacy and sustained clinical benefit.